| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiemetics | 73 | 2023 | 98 | 20.380 |
Why?
|
| Nausea | 84 | 2023 | 176 | 20.120 |
Why?
|
| Vomiting | 84 | 2023 | 195 | 19.600 |
Why?
|
| Antineoplastic Agents | 54 | 2023 | 2415 | 7.150 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 22 | 2019 | 35 | 5.460 |
Why?
|
| Quinuclidines | 17 | 2023 | 26 | 3.680 |
Why?
|
| Isoquinolines | 15 | 2023 | 72 | 3.370 |
Why?
|
| Benzodiazepines | 15 | 2022 | 67 | 3.190 |
Why?
|
| Serotonin 5-HT3 Receptor Antagonists | 15 | 2019 | 18 | 3.150 |
Why?
|
| Neoplasms | 36 | 2023 | 3041 | 3.090 |
Why?
|
| Spiro Compounds | 8 | 2019 | 25 | 2.800 |
Why?
|
| Morpholines | 14 | 2018 | 69 | 2.390 |
Why?
|
| Serotonin Antagonists | 10 | 2013 | 35 | 1.820 |
Why?
|
| Cisplatin | 20 | 2023 | 618 | 1.630 |
Why?
|
| Dexamethasone | 21 | 2023 | 344 | 1.530 |
Why?
|
| Polysorbates | 2 | 2018 | 3 | 1.280 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2018 | 203 | 1.170 |
Why?
|
| Humans | 117 | 2023 | 89357 | 1.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2020 | 2566 | 1.050 |
Why?
|
| Ondansetron | 13 | 2019 | 21 | 0.860 |
Why?
|
| Double-Blind Method | 22 | 2023 | 1719 | 0.850 |
Why?
|
| Pyridines | 4 | 2021 | 315 | 0.820 |
Why?
|
| Drug Therapy, Combination | 15 | 2019 | 784 | 0.780 |
Why?
|
| Clinical Trials, Phase III as Topic | 8 | 2021 | 175 | 0.770 |
Why?
|
| Metoclopramide | 5 | 2013 | 16 | 0.740 |
Why?
|
| Receptors, Neurokinin-1 | 6 | 2023 | 14 | 0.740 |
Why?
|
| Quality of Life | 13 | 2019 | 1668 | 0.710 |
Why?
|
| Clinical Trials as Topic | 11 | 2018 | 1150 | 0.700 |
Why?
|
| Fluid Therapy | 1 | 2020 | 51 | 0.700 |
Why?
|
| Aged, 80 and over | 25 | 2019 | 6811 | 0.690 |
Why?
|
| Aged | 41 | 2021 | 19165 | 0.650 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 200 | 0.650 |
Why?
|
| Middle Aged | 49 | 2021 | 25974 | 0.650 |
Why?
|
| Hospice Care | 3 | 2005 | 40 | 0.650 |
Why?
|
| Guideline Adherence | 1 | 2020 | 230 | 0.620 |
Why?
|
| Cyclophosphamide | 11 | 2023 | 302 | 0.620 |
Why?
|
| Female | 57 | 2023 | 46202 | 0.570 |
Why?
|
| Adult | 41 | 2021 | 26607 | 0.550 |
Why?
|
| Male | 54 | 2023 | 42411 | 0.510 |
Why?
|
| Neurotransmitter Agents | 2 | 2006 | 108 | 0.470 |
Why?
|
| Clinical Trials, Phase II as Topic | 5 | 2021 | 172 | 0.470 |
Why?
|
| Granisetron | 7 | 2016 | 8 | 0.460 |
Why?
|
| Antifungal Agents | 2 | 2005 | 120 | 0.450 |
Why?
|
| Piperazines | 3 | 2009 | 283 | 0.390 |
Why?
|
| Receptors, Serotonin, 5-HT3 | 4 | 2015 | 15 | 0.380 |
Why?
|
| Induction Chemotherapy | 5 | 2018 | 152 | 0.370 |
Why?
|
| Piperidines | 2 | 2009 | 166 | 0.360 |
Why?
|
| Chemoradiotherapy | 1 | 2013 | 309 | 0.360 |
Why?
|
| Drug Combinations | 3 | 2023 | 203 | 0.360 |
Why?
|
| Anorexia | 2 | 2009 | 30 | 0.360 |
Why?
|
| Appetite Stimulants | 1 | 2009 | 1 | 0.350 |
Why?
|
| Megestrol Acetate | 1 | 2009 | 10 | 0.340 |
Why?
|
| Drug Administration Schedule | 7 | 2021 | 895 | 0.340 |
Why?
|
| Bone Marrow Transplantation | 5 | 1999 | 283 | 0.330 |
Why?
|
| Breast Neoplasms | 7 | 2023 | 3011 | 0.330 |
Why?
|
| Anti-Bacterial Agents | 3 | 2005 | 788 | 0.330 |
Why?
|
| Administration, Oral | 8 | 2021 | 682 | 0.310 |
Why?
|
| Antipsychotic Agents | 3 | 2017 | 131 | 0.310 |
Why?
|
| Anthracyclines | 7 | 2023 | 38 | 0.300 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2007 | 19 | 0.300 |
Why?
|
| Disease Management | 2 | 2020 | 329 | 0.300 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 281 | 0.300 |
Why?
|
| Fluoxetine | 1 | 2007 | 41 | 0.300 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2016 | 1942 | 0.290 |
Why?
|
| Prospective Studies | 7 | 2023 | 4289 | 0.280 |
Why?
|
| Retrospective Studies | 4 | 2023 | 9057 | 0.280 |
Why?
|
| Radiotherapy | 2 | 2020 | 333 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2021 | 838 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 6 | 2017 | 1047 | 0.260 |
Why?
|
| Animals | 20 | 2019 | 27371 | 0.250 |
Why?
|
| Mycoses | 1 | 2005 | 46 | 0.250 |
Why?
|
| Patient Satisfaction | 4 | 2003 | 461 | 0.240 |
Why?
|
| Infusions, Intravenous | 6 | 2019 | 435 | 0.240 |
Why?
|
| Treatment Outcome | 7 | 2023 | 8241 | 0.230 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2019 | 112 | 0.230 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 2018 | 0.230 |
Why?
|
| Bacterial Infections | 1 | 2005 | 184 | 0.230 |
Why?
|
| Depression | 1 | 2007 | 505 | 0.220 |
Why?
|
| Doxorubicin | 5 | 2013 | 301 | 0.220 |
Why?
|
| Injections, Intravenous | 5 | 2019 | 240 | 0.220 |
Why?
|
| Cardiovascular System | 1 | 2003 | 63 | 0.220 |
Why?
|
| Quinolizines | 5 | 2003 | 6 | 0.200 |
Why?
|
| Education, Premedical | 1 | 2001 | 1 | 0.200 |
Why?
|
| International Educational Exchange | 1 | 2001 | 6 | 0.200 |
Why?
|
| Electrocardiography | 2 | 2003 | 494 | 0.200 |
Why?
|
| Indoles | 6 | 2013 | 314 | 0.200 |
Why?
|
| Administration, Intravenous | 2 | 2018 | 57 | 0.190 |
Why?
|
| Gastrointestinal Agents | 1 | 2023 | 172 | 0.190 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 155 | 0.180 |
Why?
|
| Terminally Ill | 1 | 2000 | 23 | 0.180 |
Why?
|
| Pilot Projects | 2 | 2020 | 871 | 0.180 |
Why?
|
| Complementary Therapies | 1 | 2020 | 56 | 0.170 |
Why?
|
| Acetals | 1 | 1999 | 3 | 0.170 |
Why?
|
| Prisoners | 1 | 1999 | 45 | 0.160 |
Why?
|
| Area Under Curve | 1 | 2019 | 337 | 0.160 |
Why?
|
| United States | 7 | 2020 | 6989 | 0.160 |
Why?
|
| Half-Life | 2 | 2017 | 97 | 0.160 |
Why?
|
| Carboplatin | 1 | 2019 | 312 | 0.160 |
Why?
|
| Palliative Care | 1 | 2000 | 264 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 435 | 0.160 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1999 | 173 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 1 | 2021 | 461 | 0.150 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 148 | 0.150 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2019 | 112 | 0.150 |
Why?
|
| Thalidomide | 1 | 2017 | 57 | 0.150 |
Why?
|
| Medicare | 1 | 2020 | 425 | 0.140 |
Why?
|
| Risk Factors | 4 | 2010 | 5499 | 0.140 |
Why?
|
| Adenocarcinoma | 3 | 2019 | 1194 | 0.140 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 69 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2001 | 645 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2019 | 385 | 0.130 |
Why?
|
| Image Enhancement | 1 | 2019 | 567 | 0.120 |
Why?
|
| Serotonin | 3 | 2023 | 221 | 0.120 |
Why?
|
| Intestinal Neoplasms | 2 | 2005 | 64 | 0.120 |
Why?
|
| Molecular Structure | 1 | 2014 | 290 | 0.120 |
Why?
|
| Contrast Media | 1 | 2019 | 1091 | 0.110 |
Why?
|
| Consensus | 3 | 2023 | 356 | 0.110 |
Why?
|
| Cross-Linking Reagents | 1 | 2013 | 87 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2019 | 669 | 0.110 |
Why?
|
| Nucleotides | 1 | 2013 | 97 | 0.110 |
Why?
|
| Aromatase Inhibitors | 2 | 1996 | 29 | 0.100 |
Why?
|
| Conserved Sequence | 1 | 2013 | 211 | 0.100 |
Why?
|
| Appetite | 3 | 2009 | 26 | 0.100 |
Why?
|
| Ultraviolet Rays | 1 | 2013 | 195 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2019 | 116 | 0.100 |
Why?
|
| Oxygen Consumption | 7 | 1992 | 244 | 0.100 |
Why?
|
| Blood Component Transfusion | 1 | 2011 | 13 | 0.100 |
Why?
|
| Thrombelastography | 1 | 2011 | 47 | 0.100 |
Why?
|
| Antibodies | 1 | 2013 | 353 | 0.090 |
Why?
|
| Safety | 2 | 2010 | 149 | 0.090 |
Why?
|
| Thromboplastin | 1 | 2010 | 7 | 0.090 |
Why?
|
| Protein C Deficiency | 1 | 2010 | 4 | 0.090 |
Why?
|
| Nitriles | 1 | 1991 | 160 | 0.090 |
Why?
|
| Endotoxemia | 1 | 2010 | 18 | 0.090 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2010 | 15 | 0.090 |
Why?
|
| Imidazoles | 1 | 1991 | 148 | 0.090 |
Why?
|
| Blood Coagulation Disorders | 1 | 2011 | 66 | 0.090 |
Why?
|
| Blood Proteins | 3 | 1978 | 146 | 0.090 |
Why?
|
| Chronic Disease | 1 | 2013 | 950 | 0.090 |
Why?
|
| Remission Induction | 5 | 2018 | 740 | 0.090 |
Why?
|
| Data Collection | 2 | 2001 | 375 | 0.090 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2010 | 156 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2011 | 280 | 0.080 |
Why?
|
| Body Weight | 2 | 2009 | 452 | 0.080 |
Why?
|
| Adolescent | 8 | 2021 | 9263 | 0.080 |
Why?
|
| Lipopolysaccharides | 1 | 2010 | 293 | 0.080 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2008 | 17 | 0.080 |
Why?
|
| Patents as Topic | 1 | 2008 | 12 | 0.080 |
Why?
|
| Contraindications | 1 | 2008 | 70 | 0.080 |
Why?
|
| Fibromyalgia | 1 | 2008 | 14 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 105 | 0.080 |
Why?
|
| Placebos | 1 | 2007 | 214 | 0.070 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 413 | 0.070 |
Why?
|
| Anxiety Disorders | 1 | 2008 | 152 | 0.070 |
Why?
|
| Anemia, Aplastic | 2 | 1984 | 32 | 0.070 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2008 | 90 | 0.070 |
Why?
|
| Child | 2 | 2017 | 7174 | 0.070 |
Why?
|
| Oxygen | 5 | 1978 | 743 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 3666 | 0.070 |
Why?
|
| Neuropharmacology | 1 | 2006 | 2 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 3448 | 0.070 |
Why?
|
| Lung Neoplasms | 5 | 2009 | 2362 | 0.070 |
Why?
|
| Carbon Dioxide | 5 | 1992 | 202 | 0.070 |
Why?
|
| Depressive Disorder, Major | 1 | 2008 | 166 | 0.070 |
Why?
|
| Cathepsin E | 1 | 2005 | 2 | 0.070 |
Why?
|
| Vagus Nerve | 1 | 2006 | 49 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 487 | 0.070 |
Why?
|
| Forecasting | 1 | 2006 | 306 | 0.060 |
Why?
|
| Hypothermia | 1 | 1984 | 26 | 0.060 |
Why?
|
| Fadrozole | 2 | 1996 | 2 | 0.060 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2004 | 39 | 0.060 |
Why?
|
| Arterioles | 4 | 1981 | 22 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 138 | 0.060 |
Why?
|
| Carcinogens | 1 | 2004 | 111 | 0.060 |
Why?
|
| Arteries | 3 | 1981 | 180 | 0.060 |
Why?
|
| Gastrointestinal Tract | 1 | 2006 | 191 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2005 | 187 | 0.060 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 1983 | 6 | 0.060 |
Why?
|
| Adenoma | 1 | 2005 | 246 | 0.060 |
Why?
|
| Diffusion | 5 | 1978 | 93 | 0.060 |
Why?
|
| Heat Exhaustion | 1 | 1983 | 1 | 0.060 |
Why?
|
| Dopamine Antagonists | 1 | 2003 | 34 | 0.060 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1983 | 58 | 0.050 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1983 | 11 | 0.050 |
Why?
|
| Sex Factors | 1 | 2006 | 1066 | 0.050 |
Why?
|
| Leukemia, Lymphoid | 1 | 1983 | 72 | 0.050 |
Why?
|
| Camptothecin | 1 | 2004 | 196 | 0.050 |
Why?
|
| Infection Control | 1 | 1984 | 120 | 0.050 |
Why?
|
| Pia Mater | 2 | 1979 | 5 | 0.050 |
Why?
|
| Carcinoma | 1 | 2005 | 443 | 0.050 |
Why?
|
| Network Meta-Analysis | 1 | 2022 | 7 | 0.050 |
Why?
|
| Kidney Diseases, Cystic | 1 | 1981 | 22 | 0.050 |
Why?
|
| Age Factors | 1 | 2006 | 1870 | 0.050 |
Why?
|
| Lorazepam | 2 | 1993 | 14 | 0.050 |
Why?
|
| Diphenhydramine | 2 | 1993 | 17 | 0.050 |
Why?
|
| School Admission Criteria | 1 | 2001 | 23 | 0.050 |
Why?
|
| Young Adult | 3 | 2021 | 6312 | 0.050 |
Why?
|
| Prognosis | 3 | 2018 | 3783 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2004 | 645 | 0.050 |
Why?
|
| Bone Marrow | 1 | 1983 | 445 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2003 | 206 | 0.050 |
Why?
|
| Survival Rate | 2 | 2018 | 1901 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2001 | 134 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 2 | 1978 | 230 | 0.040 |
Why?
|
| Brain | 3 | 2006 | 2285 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2013 | 794 | 0.040 |
Why?
|
| Fluorocarbons | 2 | 1978 | 72 | 0.040 |
Why?
|
| Headache | 2 | 1997 | 72 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 207 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2019 | 182 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 683 | 0.040 |
Why?
|
| Pancreas | 1 | 2019 | 246 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 1999 | 996 | 0.040 |
Why?
|
| Bronchi | 1 | 1978 | 229 | 0.040 |
Why?
|
| Ethics, Medical | 1 | 1999 | 307 | 0.040 |
Why?
|
| Skull | 1 | 1978 | 255 | 0.030 |
Why?
|
| Emetics | 1 | 2016 | 4 | 0.030 |
Why?
|
| Estrogen Antagonists | 1 | 1996 | 48 | 0.030 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1996 | 41 | 0.030 |
Why?
|
| Living Donors | 1 | 1999 | 339 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 780 | 0.030 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1983 | 793 | 0.030 |
Why?
|
| Phantoms, Imaging | 1 | 2019 | 448 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 341 | 0.030 |
Why?
|
| Dyssomnias | 1 | 2015 | 7 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 108 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 1981 | 638 | 0.030 |
Why?
|
| Capillaries | 2 | 1974 | 90 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 1999 | 428 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1996 | 157 | 0.030 |
Why?
|
| Genes, APC | 2 | 2005 | 27 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 657 | 0.030 |
Why?
|
| Fatigue | 1 | 2015 | 179 | 0.030 |
Why?
|
| Cats | 6 | 1981 | 305 | 0.030 |
Why?
|
| Diphosphonates | 1 | 1994 | 36 | 0.030 |
Why?
|
| Hypercalcemia | 1 | 1994 | 62 | 0.030 |
Why?
|
| Sleep Wake Disorders | 1 | 2015 | 117 | 0.030 |
Why?
|
| Aging | 1 | 2019 | 718 | 0.030 |
Why?
|
| Constipation | 1 | 1994 | 63 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 1995 | 236 | 0.030 |
Why?
|
| Diarrhea | 1 | 1994 | 182 | 0.030 |
Why?
|
| Buffers | 1 | 2013 | 26 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 135 | 0.030 |
Why?
|
| Biotin | 1 | 2013 | 45 | 0.030 |
Why?
|
| Time Factors | 6 | 2004 | 5338 | 0.030 |
Why?
|
| Receptors, Fc | 1 | 2013 | 32 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 77 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2013 | 49 | 0.030 |
Why?
|
| Nicotine | 1 | 1974 | 199 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1993 | 153 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2010 | 2001 | 0.030 |
Why?
|
| Rituximab | 1 | 2013 | 119 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2013 | 193 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2758 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 374 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2013 | 311 | 0.030 |
Why?
|
| Kinetics | 2 | 1992 | 1528 | 0.030 |
Why?
|
| Antigens | 1 | 2013 | 229 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2013 | 188 | 0.020 |
Why?
|
| Ligands | 1 | 2013 | 445 | 0.020 |
Why?
|
| Estrone | 1 | 1991 | 10 | 0.020 |
Why?
|
| Hydroxyprogesterones | 1 | 1991 | 22 | 0.020 |
Why?
|
| Androstenedione | 1 | 1991 | 29 | 0.020 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 1991 | 31 | 0.020 |
Why?
|
| Multiple Trauma | 1 | 2011 | 34 | 0.020 |
Why?
|
| Aldosterone | 1 | 1991 | 56 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 691 | 0.020 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1991 | 131 | 0.020 |
Why?
|
| Leukemia | 2 | 1983 | 323 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2013 | 479 | 0.020 |
Why?
|
| Menopause | 1 | 1991 | 76 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2013 | 465 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 3218 | 0.020 |
Why?
|
| Thrombin | 1 | 2010 | 61 | 0.020 |
Why?
|
| Disease Progression | 2 | 2005 | 1489 | 0.020 |
Why?
|
| Estradiol | 1 | 1991 | 251 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1117 | 0.020 |
Why?
|
| Radiography | 2 | 1983 | 809 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 1991 | 302 | 0.020 |
Why?
|
| Glucose | 1 | 1992 | 630 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 2062 | 0.020 |
Why?
|
| Protein Binding | 1 | 2013 | 1488 | 0.020 |
Why?
|
| Mice | 3 | 2010 | 11761 | 0.020 |
Why?
|
| Random Allocation | 1 | 1989 | 327 | 0.020 |
Why?
|
| Blood Viscosity | 1 | 1968 | 16 | 0.020 |
Why?
|
| Carcinoma, Small Cell | 1 | 1989 | 133 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 3027 | 0.020 |
Why?
|
| Erythrocytes | 2 | 1983 | 254 | 0.020 |
Why?
|
| Thymus Hormones | 1 | 1987 | 2 | 0.020 |
Why?
|
| Proteins | 1 | 1993 | 787 | 0.020 |
Why?
|
| Thymopoietins | 1 | 1987 | 7 | 0.020 |
Why?
|
| Lung | 1 | 1974 | 1263 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 1987 | 223 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 1574 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1993 | 1096 | 0.020 |
Why?
|
| Graft vs Host Disease | 2 | 1987 | 360 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1978 | 501 | 0.020 |
Why?
|
| Intestinal Diseases | 1 | 2005 | 79 | 0.020 |
Why?
|
| Lymphocytes | 2 | 1987 | 471 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 1987 | 463 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2002 | 1109 | 0.020 |
Why?
|
| Ranolazine | 1 | 2004 | 4 | 0.020 |
Why?
|
| Acetanilides | 1 | 2004 | 6 | 0.020 |
Why?
|
| Body Temperature Regulation | 1 | 1984 | 56 | 0.020 |
Why?
|
| Environment, Controlled | 1 | 1984 | 8 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2004 | 101 | 0.010 |
Why?
|
| Granulocytes | 1 | 1984 | 38 | 0.010 |
Why?
|
| Tuberculoma | 1 | 1983 | 2 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 887 | 0.010 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1983 | 27 | 0.010 |
Why?
|
| Organoplatinum Compounds | 1 | 2004 | 97 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2004 | 81 | 0.010 |
Why?
|
| Spherocytes | 1 | 1983 | 1 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1983 | 22 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1983 | 79 | 0.010 |
Why?
|
| Rhenium | 1 | 1983 | 3 | 0.010 |
Why?
|
| Technetium | 1 | 1983 | 29 | 0.010 |
Why?
|
| Sulfur | 1 | 1983 | 29 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1984 | 169 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 272 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 1983 | 47 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1983 | 221 | 0.010 |
Why?
|
| Necrosis | 1 | 1983 | 209 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2004 | 576 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1983 | 233 | 0.010 |
Why?
|
| Pulmonary Fibrosis | 1 | 1984 | 137 | 0.010 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2002 | 8 | 0.010 |
Why?
|
| Cerebrospinal Fluid | 2 | 1978 | 31 | 0.010 |
Why?
|
| Creatinine | 2 | 1993 | 293 | 0.010 |
Why?
|
| Liposomes | 1 | 2002 | 93 | 0.010 |
Why?
|
| Neutrophils | 1 | 1983 | 308 | 0.010 |
Why?
|
| Renal Artery | 1 | 1981 | 52 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 1799 | 0.010 |
Why?
|
| Critical Care | 1 | 1984 | 382 | 0.010 |
Why?
|
| Weight Loss | 2 | 1993 | 227 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 1135 | 0.010 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 1989 | 1120 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1981 | 241 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2002 | 851 | 0.010 |
Why?
|
| Brain Concussion | 1 | 1980 | 64 | 0.010 |
Why?
|
| Endothelium | 1 | 1979 | 58 | 0.010 |
Why?
|
| Solutions | 1 | 1978 | 86 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1984 | 1070 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2002 | 1534 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 1978 | 75 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2002 | 605 | 0.010 |
Why?
|
| Partial Pressure | 1 | 1977 | 50 | 0.010 |
Why?
|
| Blood Pressure | 2 | 1980 | 900 | 0.010 |
Why?
|
| Premedication | 1 | 1997 | 58 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1979 | 354 | 0.010 |
Why?
|
| Plasma Substitutes | 1 | 1977 | 9 | 0.010 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 1977 | 14 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2004 | 2872 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1984 | 3731 | 0.010 |
Why?
|
| Solubility | 1 | 1977 | 179 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1998 | 266 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1978 | 996 | 0.010 |
Why?
|
| Respiration | 1 | 1978 | 267 | 0.010 |
Why?
|
| Methotrexate | 1 | 1997 | 250 | 0.010 |
Why?
|
| Postmenopause | 1 | 1996 | 102 | 0.010 |
Why?
|
| Hypertension | 1 | 1981 | 745 | 0.010 |
Why?
|
| Acute Disease | 1 | 1997 | 841 | 0.010 |
Why?
|
| Chemistry | 1 | 1974 | 54 | 0.010 |
Why?
|
| Plants, Toxic | 1 | 1974 | 25 | 0.010 |
Why?
|
| Rats | 2 | 1978 | 4041 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1994 | 88 | 0.010 |
Why?
|
| gamma-Globulins | 1 | 1974 | 16 | 0.010 |
Why?
|
| Alpha-Globulins | 1 | 1974 | 11 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 1974 | 28 | 0.010 |
Why?
|
| Membranes | 1 | 1974 | 36 | 0.010 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 1974 | 24 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 1974 | 97 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1974 | 127 | 0.010 |
Why?
|
| Calorimetry | 1 | 1993 | 15 | 0.010 |
Why?
|
| Lipoproteins | 1 | 1974 | 136 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1993 | 34 | 0.010 |
Why?
|
| Hypoxia | 1 | 1978 | 653 | 0.010 |
Why?
|
| Glycine | 1 | 1993 | 94 | 0.010 |
Why?
|
| Calorimetry, Indirect | 1 | 1992 | 14 | 0.010 |
Why?
|
| Chlorides | 1 | 1993 | 103 | 0.010 |
Why?
|
| Heart Failure | 1 | 2002 | 1185 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1992 | 80 | 0.010 |
Why?
|
| Potassium | 1 | 1993 | 253 | 0.010 |
Why?
|
| Sodium | 1 | 1993 | 331 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1992 | 388 | 0.010 |
Why?
|
| Biological Transport | 1 | 1971 | 401 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1974 | 672 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 1992 | 277 | 0.010 |
Why?
|
| Calcium | 1 | 1994 | 1175 | 0.010 |
Why?
|
| Body Mass Index | 1 | 1993 | 773 | 0.010 |
Why?
|
| Microcirculation | 2 | 1980 | 104 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1992 | 836 | 0.000 |
Why?
|
| Vasodilation | 2 | 1978 | 93 | 0.000 |
Why?
|
| Blood Flow Velocity | 1 | 1968 | 200 | 0.000 |
Why?
|
| Thymopentin | 1 | 1987 | 2 | 0.000 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1987 | 25 | 0.000 |
Why?
|
| Antibody Formation | 1 | 1987 | 171 | 0.000 |
Why?
|
| Graft Survival | 1 | 1987 | 900 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1981 | 141 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1981 | 511 | 0.000 |
Why?
|
| Platelet Aggregation | 1 | 1980 | 44 | 0.000 |
Why?
|
| Hypotension | 1 | 1980 | 71 | 0.000 |
Why?
|
| Pentylenetetrazole | 1 | 1978 | 2 | 0.000 |
Why?
|
| Vasoconstriction | 1 | 1978 | 92 | 0.000 |
Why?
|
| Regional Blood Flow | 1 | 1978 | 198 | 0.000 |
Why?
|
| Homeostasis | 1 | 1980 | 417 | 0.000 |
Why?
|
| Emulsions | 1 | 1977 | 19 | 0.000 |
Why?
|
| Seizures | 1 | 1978 | 306 | 0.000 |
Why?
|
| Cerebral Cortex | 1 | 1978 | 589 | 0.000 |
Why?
|